The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old

被引：0

作者：

Mcleod, C. ^{[1
,2
,3
,4
]}

Dymock, M. ^{[1
,5
]}

Flanagan, Kl ^{[6
,7
,8
,20
,23
]}

Plebanski, M. ^{[8
]}

Marshall, Hs ^{[9
,10
,11
]}

Estcourt, Mj ^{[4
]}

Wadia, U. ^{[1
,2
,3
]}

Tjiam, Mc ^{[1
]}

Blyth, Cc ^{[1
,2
,3
,12
]}

Subbarao, K. ^{[13
,14
]}

Mordant, Fl ^{[14
]}

Nicholson, S. ^{[15
,16
]}

Cain, N. ^{[14
]}

Brizuela, R. ^{[14
]}

Faust, Sn ^{[17
,18
,19
]}

Thornton, Rb ^{[1
,3
]}

Ellis, Z. ^{[1
]}

Mckenzie, A. ^{[21
]}

Marsh, Ja ^{[1
,3
]}

Snelling, Tl ^{[4
]}

Richmond, Pc ^{[1
,3
,22
]}

机构：

[1] Wesfarmers Ctr Vaccines & Infect Dis, Kids Res Inst Australia, Nedlands, Australia

[2] Perth Childrens Hosp, Dept Infect Dis, Nedlands, WA, Australia

[3] Univ Western Australia, Ctr Child Hlth Res, Crawley, Australia

[4] Univ Sydney, Fac Med & Hlth, Sydney Sch Publ Hlth, Sydney, Australia

[5] Univ Western Australia, Sch Populat & Global Hlth, Nedlands, Australia

[6] Launceston Gen Hosp, Clifford Craig Fdn, Tasmanian Vaccine Trial Ctr, Hobart, Australia

[7] Univ Tasmania, Coll Hlth & Med, Sch Hlth Sci, Launceston, Tas, Australia

[8] Royal Melbourne Inst Technol RMIT Univ, Sch Sci, Melbourne, Vic, Australia

[9] Womens & Childrens Hlth Network, North Adelaide, Australia

[10] Univ Adelaide, Robinson Res Inst, Adelaide, Australia

[11] Univ Adelaide, Adelaide Med Sch, Adelaide, Australia

[12] QEII Med Ctr, PathWest Lab Med WA, Dept Microbiol, Nedlands, Australia

[13] WHO Collaborating Ctr Reference & Res Influenza, Parkville, Vic, Australia

[14] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Australia

[15] Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Reference Lab, Melbourne, Australia

[16] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Australia

[17] Univ Hosp Southampton NHS Fdn Trust, Southampton Clin Res Facil, Natl Inst Hlth Res, Southampton, England

[18] Univ Hosp Southampton NHS Fdn Trust, Biomed Res Ctr, Southampton, England

[19] Univ Southampton, Fac Med, Southampton, England

[20] Univ Southampton, Inst Life Sci, Southampton, England

[21] Kids Res Inst Australia, Nedlands, Australia

[22] Perth Childrens Hosp, Gen Paediat Dept, Nedlands, WA, Australia

[23] Perth Childrens Hosp, Immunol Dept, Nedlands, Australia

来源：

JOURNAL OF INFECTION | 2024年 / 89卷 / 06期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

COVID-19; Vaccination; Adaptive trial; Policy; Immunisation; SARS-COV-2; VACCINES;

D O I：

10.1016/j.jinf.2024.106346

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84. Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible. Participants were randomly allocated to BNT162b2, mRNA-1273 or NVX-CoV2373 1:1:1. The log(10) concentration of anti-spike Ig Total was summarised as the geometric mean concentration (GMC). Reactogenicity and safety outcomes were captured. Results: Between Mar 2022 and Aug 2023, 743 participants were recruited to the trial and had D28 samples available. Of these, 120 and 103 belonged to the 18-<50 y and 50-<70 y strata, respectively. The mean adjusted GMCs (95% credible intervals) peaked at D28; these were 41 262 (31 611, 51 105), 45 585 (34 194, 57 441) and 25 281 (20 021, 31 234) U/mL in the 18-<50 y stratum and 30 753 (25 071, 36 704), 35 132 (27 523, 42 239) and 17 322 (13 983, 20 641) U/mL in the 50-<70 y stratum following BNT162b2, mRNA-1273 and NVX-CoV2373, respectively. Limited neutralisation against Omicron subvariants was found following boosting with all vaccines. There were 4 possibly or probably-related adverse events in the 18-<50 y stratum and 5 events in the 50-<70 y stratum, and severe reactogenicity events were <10% and <11% in these strata, respectively. Conclusions: Vaccines targeting Ancestral virus elicited boosted antibody responses to Ancestral virus but minimal neutralising antibody against Omicron variants. (c) 2024 Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页数：10

共 47 条

[41] Infection with SARS-CoV-2 following Second Dose Pfizer-BioNTech mRNA COVID-19 Vaccine BNT162b2 in Danish Adolescents Aged 12-18 Years: A Real-World Nationwide Danish Cohort Study
Birk, Nina Marie
Christensen, Anne Vinggaard
Nygaard, Ulrikka
Bundgaard, Henning
Nielsen, Susanne Dam
Berg, Selina Kikkenborg
Wallach-Kildemoes, Helle
VIRUSES-BASEL, 2024, 16 (01):
[42] Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial
Xu, Jia-Wei
Wang, Bu-Sen
Gao, Ping
Huang, Hai-Tao
Wang, Fei-Yu
Qiu, Wei
Zhang, Yuan-Yuan
Xu, Yu
Gou, Jin-Bo
Yu, Lin-Ling
Liu, Xuan
Wang, Rui-Jie
Zhu, Tao
Hou, Li-Hua
Qing-Wang
EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
[43] BNT162b2 mRNA Vaccination Against COVID-19 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021-April 2022
Zambrano, Laura D.
Newhams, Margaret M.
Olson, Samantha M.
Halasa, Natasha B.
Price, Ashley M.
Orzel, Amber O.
Young, Cameron C.
Boom, Julie A.
Sahni, Leila C.
Maddux, Aline B.
Bline, Katherine E.
Kamidani, Satoshi
Tarquinio, Keiko M.
Chiotos, Kathleen
Schuster, Jennifer E.
Cullimore, Melissa L.
Heidemann, Sabrina M.
Hobbs, Charlotte, V
Nofziger, Ryan A.
Pannaraj, Pia S.
Cameron, Melissa A.
Walker, Tracie C.
Schwartz, Stephanie P.
Michelson, Kelly N.
Coates, Bria M.
Flori, Heidi R.
Mack, Elizabeth H.
Smallcomb, Laura
Gertz, Shira J.
Bhumbra, Samina S.
Bradford, Tamara T.
Levy, Emily R.
Kong, Michele
Irby, Katherine
Cvijanovich, Natalie Z.
Zinter, Matt S.
Bowens, Cindy
Crandall, Hillary
Hume, Janet R.
Patel, Manish M.
Campbell, Angela P.
Randolph, Adrienne G.
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E90 - E100
[44] Safety of Ancestral Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 Years
Hu, Mao I.
Shoaibi, Azadeh
Feng, Yuhui
Lloyd, Patricia C.
Wong, Hui-Lee
Smith, Elizabeth R.
Amend, Kandace L.
Kline, Annemarie
Beachler, Daniel
Gruber, Joann F.
Mitra, Mahasweta
Seeger, John D.
Secora, Alex
Obidi, Joyce
Wang, Jing
Song, Jennifer
McMahill-Walraven, Cheryl N.
Reich, Christian
McEvoy, Rowan
Do, Rose
Chillarige, Yoganand
Clifford, Robin
Forshee, Richard A.
Anderson, Steven A.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 700 - 701
[45] Immunogenicity, safety, and reactogenicity of a halfversus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
Batmunkh, Tsetsegsaikhan
Moore, Kerryn A.
Thomson, Helen
Altangerel, Bolor
Amraa, Otgonjargal
Avaa, Naranbaatar
Batbayar, Lkhagvagaram
Batsukh, Khishigjargal
Bright, Kathryn
Burentogtokh, Tsogjargal
Do, Lien Anh Ha
Dorj, Gantuya
Hart, John D.
Javkhlantugs, Khulan
Jigjidsuren, Sarantsetseg
Justice, Frances
Li, Shuo
V. Licciardi, Paul
Mashbaatar, Khaliunaa
Mazarakis, Nadia
Neal, Eleanor F. G.
Nguyen, Cattram Duong
Ochirbat, Batbayar
Tsolmon, Bilegtsaikhan
Tuya, Alimaa
Surenjav, Unursaikhan
von Mollendorf, Claire
Mulholland, Kim
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 42
[46] Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
Corominas, Julia
Garriga, Carme
Prenafeta, Antoni
Moros, Alexandra
Canete, Manuel
Barreiro, Antonio
Gonzalez-Gonzalez, Luis
Madrenas, Laia
Guell, Irina
Clotet, Bonaventura
Izquierdo-Useros, Nuria
Raich-Regue, Dalia
Gallemi, Marcal
Blanco, Julia
Pradenas, Edwards
Trinite, Benjamin
Prado, Julia G.
Blanch-Lombarte, Oscar
Perez-Caballero, Raul
Plana, Montserrat
Esteban, Ignasi
Pastor-Quinones, Carmen
Nunez-Costa, Xavier
Abu Taleb, Rachel
McSkimming, Paula
Soriano, Alex
Nava, Jocelyn
Anagua, Jesse Omar
Ramos, Rafel
Lluch, Ruth Marti
Comes, Aida Corpes
Romero, Susana Otero
Gomez, Xavier Martinez
Sans-Pola, Carla
Molto, Jose
Benet, Susana
Bailon, Lucia
Arribas, Jose R.
Borobia, Alberto M.
Parada, Javier Queiruga
Navarro-Perez, Jorge
Giner, Maria Jose Forner
Lucas, Rafael Orti
Jimenez, Maria del Mar Vazquez
Compan, Salvador Ona
Alvarez-Mon, Melchor
Troncoso, Daniel
Arana-Arri, Eunate
Meijide, Susana
Imaz-Ayo, Natale
LANCET REGIONAL HEALTH-EUROPE, 2023, 28
[47] Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial
Yang, Bei-Fang
Jin, Jing
He, Xi-Ran
Yang, Zhong-Hua
Qian, Xiao'ai
Tong, Ye-Qing
Ke, Chang-Xian
Li, Zhao-Hong
Li, Zhao-Xia
Zhong, Lin-Feng
Gan, Ze-Hong
Zhang, Xian-Feng
Zeng, Ying
EXPERT REVIEW OF VACCINES, 2025, 24 (01) : 81 - 90

← 1 2 3 4 5 →